When it comes to switching from a biologic to a biosimilar drug, patient choice and engagement is extremely important, according to Durhane Wong-Rieger, president and chief executive officer of the Canadian Organization for Rare Disorders. “While a patient’s on a drug, they need to be continuously monitoring,” she said during a session at Benefits Canada’s 2019 Calgary Drug […]
With around 270,000 individuals currently affected by irritable bowel disease, Canada has the highest prevalence in the world, according to Mina Mawani, president and chief executive officer of Crohn’s and Colitis Canada, during a session at Benefits Canada’s 2019 Halifax Benefits Summit on Sept. 24. “And this is going to increase significantly. We’re going to be […]
Sixty per cent of all prescriptions in Canada are paid for by employer-provided drug plans and some have life-time limits for biologic reimbursement. However, transitioning to a biosimilar could extend this limit for patients, said Dr. John Esdaile, scientific director at Arthritis Research Canada, during Benefits Canada’s Halifax Benefits Summit on Sept. 24. Biologic drugs are derived through […]
A group of institutional investors representing more than US$500 billion is calling on the U.S. Congress to vote down the Canada-United States-Mexico trade agreement to prevent extended monopoly rights for pharmaceutical companies in all three countries. The Interfaith Center on Corporate Responsibility, which represents more than 300 religious institutional investors, pension funds, foundations, asset managers […]
The Health Association of Nova Scotia, which has a number of different employers in its benefits plan, cites rheumatoid arthritis medications as its top drugs in terms of cost. “Chronic disease, in terms of inflammatory disease — not just for rheumatoid, but for Crohn’s disease as well — those are what we’re seeing from a […]
If the Canada-United States-Mexico trade agreement goes through it could have a significant impact on the cost of private drug plans. Currently on hold until members of Parliament return to Ottawa after the summer break, the agreement as written would extend the data protection term for biologic drugs to 10 years from the current eight. If […]
Inflammatory conditions have the power to severely affect employees’ productivity and general quality of life. But new biologic treatments are raising the success rates for sufferers, according to Aaron Sihota, primary care pharmacist and clinical instructor at the University of British Columbia’s faculty of pharmaceutical sciences, at Benefits Canada’s 2019 Vancouver Benefits Summit at the Fairmont Waterfront Hotel on May 24. “Why […]
Inflammatory conditions have the power to severely affect employees’ productivity and general quality of life. But new biologic treatments are raising the success rates for sufferers, according to Aaron Sihota, primary care pharmacist and clinical instructor at the University of British Columbia’s faculty of pharmaceutical sciences, at Benefits Canada’s 2019 Vancouver Benefits Summit at the Fairmont Waterfront Hotel on May 24. “Why […]
On May 22, the 2019 Calgary Benefits Summit focused on how employers can make their organization its healthiest by starting with their benefits plans. Here’s what you missed! How a Blue Zone concept can benefit the workplace What can a small Alberta town of 70,000 people do when the provincial government’s response to, “We need […]
British Columbia is expanding its use of biosimilars, effective November 2019. The move is expected to create opportunities for new drug listings and increase current coverage for patients, according to a press release from the B.C. government. The first two drugs to come into immediate effect are Jardiance, a diabetes drug, and Taltz, an arthritis drug. It will change the game considerably, says Suzanne Lepage, a private […]